These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

650 related articles for article (PubMed ID: 28101432)

  • 21. Hemolytic uremic syndrome with dual caution in an infant: cobalamin C defect and complement dysregulation successfully treated with eculizumab.
    Barlas UK; Kıhtır HS; Goknar N; Ersoy M; Akcay N; Sevketoglu E
    Pediatr Nephrol; 2018 Jun; 33(6):1093-1096. PubMed ID: 29558000
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Atypical Hemolytic Uremic Syndrome: A Meta-Analysis of Case Reports Confirms the Prevalence of Genetic Mutations and the Shift of Treatment Regimens.
    Krishnappa V; Gupta M; Elrifai M; Moftakhar B; Ensley MJ; Vachharajani TJ; Sethi SK; Raina R
    Ther Apher Dial; 2018 Apr; 22(2):178-188. PubMed ID: 29250893
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Case series: coronavirus disease 2019 infection as a precipitant of atypical hemolytic uremic syndrome: two case reports.
    Kurian CJ; French Z; Kukulich P; Lankiewicz M; Ghimire S; Maarouf OH; Rizk S; Rhoades R
    J Med Case Rep; 2021 Dec; 15(1):587. PubMed ID: 34903272
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A Rare Case of Lupus Nephritis Presenting as Thrombotic Microangiopathy with Diffuse Pseudotubulization Possibly Caused by Atypical Hemolytic Uremic Syndrome.
    Ono M; Ohashi N; Namikawa A; Katahashi N; Ishigaki S; Tsuji N; Isobe S; Iwakura T; Sakao Y; Tsuji T; Kato A; Fujigaki Y; Shimizu A; Yasuda H
    Intern Med; 2018 Jun; 57(11):1617-1623. PubMed ID: 29434134
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Terminal Complement Inhibitor Eculizumab in Adult Patients With Atypical Hemolytic Uremic Syndrome: A Single-Arm, Open-Label Trial.
    Fakhouri F; Hourmant M; Campistol JM; Cataland SR; Espinosa M; Gaber AO; Menne J; Minetti EE; Provôt F; Rondeau E; Ruggenenti P; Weekers LE; Ogawa M; Bedrosian CL; Legendre CM
    Am J Kidney Dis; 2016 Jul; 68(1):84-93. PubMed ID: 27012908
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Atypical Hemolytic Uremic Syndrome and Chronic Ulcerative Colitis Treated with Eculizumab.
    Webb TN; Griffiths H; Miyashita Y; Bhatt R; Jaffe R; Moritz M; Hofer J; Swiatecka-Urban A
    Int J Med Pharm Case Reports; 2015; 4(5):105-112. PubMed ID: 27135055
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Safety and effectiveness of eculizumab for pediatric patients with atypical hemolytic-uremic syndrome in Japan: interim analysis of post-marketing surveillance.
    Ito S; Hidaka Y; Inoue N; Kaname S; Kato H; Matsumoto M; Miyakawa Y; Mizuno M; Okada H; Shimono A; Matsuda T; Maruyama S; Fujimura Y; Nangaku M; Kagami S
    Clin Exp Nephrol; 2019 Jan; 23(1):112-121. PubMed ID: 30039480
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Atypical hemolytic uremic syndrome: when pregnancy leads to lifelong dialysis: a case report and literature review.
    Cadet B; Meshoyrer D; Kim Z
    Cardiovasc Endocrinol Metab; 2021 Dec; 10(4):225-230. PubMed ID: 34765894
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Atypical Hemolytic Uremic Syndrome in a Pregnant Patient with a Thrombomodulin Gene Variant Treated with Plasma Exchange and Eculizumab.
    Kannan L
    Am J Case Rep; 2023 Apr; 24():e938896. PubMed ID: 37120715
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Long-term eculizumab improves clinical outcomes in atypical hemolytic uremic syndrome.
    Vilalta R; Lara E; Madrid A; Chocron S; Muñoz M; Casquero A; Nieto J
    Pediatr Nephrol; 2012 Dec; 27(12):2323-6. PubMed ID: 22890512
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pregnancy-Associated Atypical Hemolytic Uremic Syndrome Successfully Treated with Ravulizumab: A Case Report.
    Miyazaki Y; Fukuda M; Hirayu N; Nabeta M; Takasu O
    Cureus; 2024 Feb; 16(2):e54207. PubMed ID: 38496102
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Coexistence of atypical hemolytic uremic syndrome and crescentic IgA nephropathy treated with eculizumab: a case report.
    Matsumura D; Tanaka A; Nakamura T; Sato E; Node K
    Clin Nephrol Case Stud; 2016; 4():24-28. PubMed ID: 29043138
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Severe and malignant hypertension are common in primary atypical hemolytic uremic syndrome.
    Cavero T; Arjona E; Soto K; Caravaca-Fontán F; Rabasco C; Bravo L; de la Cerda F; Martín N; Blasco M; Ávila A; Huerta A; Cabello V; Jarque A; Alcázar C; Fulladosa X; Carbayo J; Anaya S; Cobelo C; Ramos N; Iglesias E; Baltar J; Martínez-Gallardo R; Pérez L; Morales E; González R; Macía M; Draibe J; Pallardó L; Quintana LF; Espinosa M; Barros X; Pereira F; Cao M; Moreno JA; Rodríguez de Córdoba S; Praga M;
    Kidney Int; 2019 Oct; 96(4):995-1004. PubMed ID: 31420192
    [TBL] [Abstract][Full Text] [Related]  

  • 34. An adult case of atypical hemolytic uremic syndrome presented with posterior reversible encephalopathy syndrome: Successful response to late-onset eculizumab treatment.
    Medeni SS; Namdaroglu S; Cetintepe T; Ozlu C; Tasli F; Adibelli ZH; Bilgir O; Tatar E
    Hematol Rep; 2018 Sep; 10(3):7553. PubMed ID: 30344987
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Atypical hemolytic-uremic syndrome due to complement factor I mutation.
    Almalki AH; Sadagah LF; Qureshi M; Maghrabi H; Algain A; Alsaeed A
    World J Nephrol; 2017 Nov; 6(6):243-250. PubMed ID: 29226095
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Atypical hemolytic uremic syndrome in an elderly patient successfully treated with eculizumab].
    Fukasawa C; Ooishi S; Kumagai T; Koshiisi M; Sueki Y; Nakajima K; Mitsumori T; Yoshida Y; Kato H; Nangaku M; Miyata T; Kirito K
    Rinsho Ketsueki; 2018; 59(2):182-186. PubMed ID: 29515071
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Efficacy and safety of eculizumab in childhood atypical hemolytic uremic syndrome in Japan.
    Ito N; Hataya H; Saida K; Amano Y; Hidaka Y; Motoyoshi Y; Ohta T; Yoshida Y; Terano C; Iwasa T; Kubota W; Takada H; Hara T; Fujimura Y; Ito S
    Clin Exp Nephrol; 2016 Apr; 20(2):265-72. PubMed ID: 26156042
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effect of eculizumab and recombinant human soluble thrombomodulin combination therapy in a 7-year-old girl with atypical hemolytic uremic syndrome due to anti-factor H autoantibodies.
    Udagawa T; Motoyoshi Y; Matsumura Y; Takei A; Ariji S; Ito E; Chiga M; Nagasawa M; Morio T; Mizutani S
    CEN Case Rep; 2014 May; 3(1):110-117. PubMed ID: 28509254
    [TBL] [Abstract][Full Text] [Related]  

  • 39. An effective treatment of atypical hemolytic uremic syndrome with plasma exchange and eculizumab: A case report.
    Sengul Samanci N; Ayer M; Ergen A; Ozturk S
    Transfus Apher Sci; 2015 Jun; 52(3):314-6. PubMed ID: 25634788
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Three months interval therapy of Eculizumab in a patient with atypical hemolytic uremic syndrome with hybrid CFHR1/CFH gene.
    Alobaidi S; AlDabbagh A; Alamoudi A; Almowarey M; Akl A
    CEN Case Rep; 2019 May; 8(2):139-143. PubMed ID: 30715674
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 33.